阿替洛尔对哮喘合并心梗疗效观察

Effect and tolerance of the therapy with Atenolol on asthma combined acute myocardial infarction

目的探讨β受体阻滞剂阿替洛尔对哮喘合并心梗的治疗效果及耐受情况。方法将42例哮喘合并心梗患者随机分为治疗组(n=20)和对照组(n=22),两组均采用常规治疗,治疗组在常规治疗基础上加用阿替洛尔,观察病人治疗效果及耐受情况。在最初3周,每周测定一次血清肿瘤坏死因子-α(TNF-α)、γ-干扰素(IFN-γ)和最大呼气流速(PEF)。结果治疗组临床症状、心电图、心肌酶谱达到治疗目的,无明显哮喘加重。治疗组与对照组治疗3周对血清TNF-α、IFN-γ、PEF指标的变化均无统计学意义(P>0.05)。结论阿替洛尔对哮喘合并心梗时疗效肯定,无明显哮喘加重。

Objective： To evaluate the effect and tolerance of the therapy with Atenolol on asthma combined acute myocardial infarction.Methods： Forty-two patients of asthma cumbined acute myocardial were divided into two groups at random.Twenty cases were treated with both common therapy and atenolol,the effect and telerance of patients were recorded and the TNF-α,IFN-γ and PEF per week for first three weeks were examined.Results： The treatment was effective in the clinical symptom,ECG and CPK-MB in the therapy group with no asthma worsening.For the three weeks in therapy of the therapy group and the control group,the comparison for each item（TNF-α,IFN-γ,PEF） was not significant（P〉0.05）.Conclusion： Atenolol has the positive effect on the therapy of asthmas combined acute myocardial infarction and asthma does not get worse.